Chimpanzee adenovirus serotype 68 vector (AdC68 vector)

Chimpanzee adenovirus serotype 68 vector is a non-human, replication-defective adenoviral vector that has been engineered to deliver genes or vaccine antigens into mammalian cells. The genome of AdC68 shares substantial similarity with human adenoviruses, particularly subgroup E (type 4), but has key differences—especially in hexon hypervariable regions—making it less susceptible to neutralizing antibodies common in humans[1]. This allows AdC68 to efficiently transduce human and animal cells, making it a popular platform for vaccine development, gene therapy, and immunotherapy. AdC68-based vaccines have shown high transduction efficiency, robust antigen expression, broad cell tropism, genetic stability, and strong T- and B-cell responses in experimental studies. Notably, pre-existing immunity to AdC68 in humans is low, bypassing a major limitation of human-derived adenoviral vectors[1][3][4]. AdC68 serves as a carrier rather than a classical drug target. Its safety profile compares favorably with human adenoviral vectors, though immune and inflammatory reactions remain considerations[3][4].

Other names

AdC68 vectorAdC68ChAd68Chimpanzee adenovirus vectorChimpanzee adenovirus serotype 68

Transduction of human or animal cells, leading to expression of delivered genes or vaccine antigens Induction of robust B- and T-cell immune responses against encoded antigens